18694-40-1

Usage

Uses

Used in Pharmaceutical Industry:
Epirizole is used as an analgesic and anti-inflammatory agent for its ability to relieve pain and reduce inflammation without causing acidity.
Used in Diabetes Research:
Epirizole is used as a research compound for its potential role in inducing the differentiation of insulin-producing ti-cells in larval zebrafish, which may have implications for the development of new treatments for diabetes.
Used in Pharmaceutical Research:
Epirizole is used as a research compound for its ability to increase the expression of MDR1 mRNA in Caco-2 cells, which may have potential applications in the development of new drugs and drug delivery systems.

Originator

Mebron,Daiichi Seiyaku,Japan,1970

Manufacturing Process

A mixture of 16.3 g of 4-methyl-6-methoxy-2-pyrimidinyl-hydrazine,13.7 g of ethyl acetoacetate and 16.3 ml of methanol was refluxed 2 hours on a water bath. After a mixture of 4.7 g of sodium hydroxide, 4.7 ml of water and 27 ml of methanol was added dropwise thereto at about 50°C, the reaction mixture was refluxed for 2 hours more, then methanol was distilled off and the residue was dissolved in 130 ml of water. The solution was adjusted to pH 6 with acetic acid. The precipitate was filtered, washed with water and dried to give 24 g (yield: 95.3%) of crystals, MP 97° to 98°C. Recrystallization from ligroin gave 1-(4'-methyl-6'-methoxy-2'-pyrimidinyl)-3-methyl-3-pyrazoline-5-one, MP 102° to 103°C.To a solution of 4.76 g of 1-( 4'-methyl-6'-methoxy-2'-pyrimidinyl)-3-methyl- 3-pyrazoline 5-one in 200 ml of ether was added an ether solution containing 6 molar equivalents of diazomethane and the reaction mixture was allowed to stand at room temperature for 20 hours. After distilling off the solvent, the residue was dissolved in 160 ml of water, made alkaline (pH 10) with sodium hydroxide solution and extracted three times with 140 ml of benzene. The extract was washed with a small amount of water, dried over sodium sulfate and evaporated to give a crystalline mass. Recrystallization from isopropylether gave 1-(4'-methyl-6'-methoxy-2'-pyrimidinyl)-3-methyl-5- methoxypyrazole (3.96 g, 84%) as color less prisms, MP 90° to 92°C.

Therapeutic Function

Antiinflammatory, Analgesic, Antipyretic

InChI:InChI=1/C10H12N4O2/c1-7-6-9(16-3)14(13-7)10-11-5-4-8(12-10)15-2/h4-6H,1-3H3

Relevant academic research and scientific papers

Synthesis and crystal structure of (p-CH3C6H4NH3)6P6O18·8H2O

Preparation and complete structural characterization by X-ray diffraction (XRD), IR absorption, thermogravimetric and differential thermal analysis (TG-DTA), and mass angle spinning (MAS) NMR spectroscopy are given for a new cyclohexaphosphate, (p-CH3C6H4NH3)6P6O18·8H2O. This compound is monoclinic in space group P21/c, with Z = 2 and unit-cell parameters a = 10.695(6), b = 24.952(8), c = 11.163(4) angstrom, and β = 97.53(4)°. The crystal structure was solved and refined down to R = 0.036, using 4168 independent reflections. The atomic arrangement can be described as layer organization. Layers built by P6O18 ring anions and water molecules spread parallel to the plane (010). Between these layers are located the organic groups that form hydrogen bonds with P6O18 ring oxygens. Geometrical characteristics of the hydrogen bonds are described.

Synthesis and crystal structure of(1,6-NH3C6H12NH3) 2(1-NH3C10H7)2P 6O18.2H2O

Synthesis and complete structural characterization by X-ray diffraction, DTA, GTA and IR are given for a new cyclohexaphosphate: (1,6-NH3C6H12NH3) 2(1-NH3C10H7)2P 6O18.2H2O. This compound is monoclinic P21/c with the following unit-cell parameters: a = 11.861(2)A, b = 10.104(1)A, c = 19.664(6)A, β = 96.44(2)°, and Z = 2. The crystal structure has been solved and refined to R = 0.033 using 3928 independent reflections. The atomic arrangement can be described as layer organisation. Layers built by P6O18 ring anions and water molecules spread in the plans (100). Between these layers are located the organic groups which form hydrogen bonds with oxygen atoms of P6O18 rings and water molecules. Geometrical characteristics of hydrogen bonds are described. The reported IR study is supported by a delaited theoretical group analysis applied to P6O18 with D6h, ideal local symmetry. Elsevier.

Synthesis and crystal structure of (o-CH3C6H4NH3)6P6O18*2H2O

(o-CH3C6H4NH3)6P6O18*2H2O is triclinic, P1-, with Z = 1 and the following unit-cell dimensions: a = 10.395(4), b = 10.793(5), c = 13.839(4)?, alpha. = 103.98(3), β = 91.62(3), γ = 116.65(3)° Itscrystal structure has been determined and refined down to R = 0.036, us ing 5850 independent reflections. Among the three crystallographically independent CH3-C6H4-NH3 groups one is disordered. All the H-atoms belonging to the nondisorderd ligands have been located and refined. The hydrogen-bond distribution is carefully described.

Chemical preparation, thermal behavior and crystal structure of calcium-cesium cyclohexaphosphate dihydrate

Chemical preparation and crystal structure are given for a new monovalent-divalent cation cyclohexaphosphate. This compound is monoclinic P21/c with the following unit cell parameters: a = 9.087(2), b = 12.246(4), c = 9.895(4) A, β = 116.98(2)°, Z = 2, V = 981(1) A3, and Dx = 2.897 g·cm-3. The atomic arrangement can be described as successive wide layers made by the P6O18 ring anions and interconnected by the CaO6 and CsO8 polyhedra and the hydrogen bonds. Crystal structure was solved with a final R value of 0.032 for 6263 independent reflections. The thermal behavior has been investigated and interpreted by comparison with IR absorption spectroscopy and X-ray diffraction experiments.

Structural characterization of a series of cyclohexaphosphates: Ca2M2P6O18 · 6H2O (M = K, Tl, Rb)

Three new cyclohexaphosphates with the general formula Ca2M2P6O18 · 6H2O (M = K, Tl, Rb) are reported. They crystallize with monoclinic unit cells and are isotopic. As an example the paramters of Ca2K2P6O18 · 6H2O are a = 7.266(1), b = 11.833(2), c = 12.300(2) A, β = 103.17(1)0, Z = 2, P21In, V = 1030(3) A3, and Dx = 2.387 g cm-3. Crystal structure of this phase was determined using 6292 independent reflections with a final R = 0.025. The atomic arrangement can be described as puckered layers containing water bonded P6O18 anions and Ca2+ and K+ cations, alternating along the (1, 0, 1) direction. Synthesis and characterization by X-ray diffraction, IR absorption, and TA are described.

Synthesis and crystal structure of cesium-lithium cyclo-hexaphosphate dihydrate

Cs3Li3P6O182H2O is triclinic, P1ˉ, with Z = 1 and the following unit-cell dimensions: a = 7.938 (2), b = 7.674 (2), c = 9.556 (2), α = 113.39 (4), β = 93.83 (4), γ = 83.00 (4). The crystal structure w

Water dispersion containing ultrafine particles of organic compounds

A water-dispersible condensate of water-insoluble ultrafine particles of medicine or hormones having a particle size of at largest 4 μm prepared by the steps of heating the medicine or hormone in a vacuum vessel at a temperature of 30° C. higher than the boiling point and at a pressure between 0.01 Torr and 10 Torr to evaporate the medicine or hormone and condensing the medicine or hormone on a recovery plate to obtain the condensate.